Symbiotec Pharmalab Profile
Key Indicators
- Authorised Capital ₹ 12.00 Cr
as on 29-06-2024
- Paid Up Capital ₹ 10.94 Cr
as on 29-06-2024
- Company Age 22 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 291.46 Cr
as on 29-06-2024
- Satisfied Charges ₹ 104.58 Cr
as on 29-06-2024
- Revenue 1.21%
(FY 2022)
- Profit -54.46%
(FY 2022)
- Ebitda -48.29%
(FY 2022)
- Net Worth 9.76%
(FY 2022)
- Total Assets 6.25%
(FY 2022)
About Symbiotec Pharmalab
The Corporate was formerly known as Symbiotec Pharmalab Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 12.00 Cr and a paid-up capital of Rs 10.94 Cr.
The company currently has active open charges totaling ₹291.46 Cr. The company has closed loans amounting to ₹104.58 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Symbiotec Pharmalab Private Limited India are Salil Jain as COMPANY SECRETARY and Raghavender Ramachandran as Cfo. Sumit Gupta, Shankar Gopalakrishnan, Anil Satwani, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232MP2002PTC015293
- Company No.
015293
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Sep 2002
- Date of AGM
23 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Symbiotec Pharmalab Private Limited offer?
Symbiotec Pharmalab Private Limited offers a wide range of products and services, including Respiratory System Drugs, Anti Asthma Drug, Housekeeping and Cleaning Services, Commercial Cleaning Services, Medical Consultants & Clinics, Medical Consultancy Services.
Who are the key members and board of directors at Symbiotec Pharmalab?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Salil Jain | Company Secretary | 11-May-2018 | Current |
| Raghavender Ramachandran | CFO | 04-Feb-2022 | Current |
Anil Satwani  | Managing Director | 20-Sep-2002 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sumit Gupta | Nominee Director | 06-Dec-2018 | Current |
| Rohit Mantri | Nominee Director | 06-Dec-2018 | Current |
| Shankar Gopalakrishnan | Nominee Director | 06-Dec-2018 | Current |
Financial Performance and Corporate Structure Insights of Symbiotec Pharmalab.
Symbiotec Pharmalab Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 1.21% increase. The company also saw a substantial fall in profitability, with a 54.46% decrease in profit. The company's net worth moved up by a moderate rise of 9.76%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Symbiotec Pharmalab?
In 2022, Symbiotec Pharmalab had a promoter holding of 25.08% and a public holding of 74.92%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Symbiotec Lifesciences Private Limited
Active 4 years 2 monthsSumit Gupta, Anil Satwani and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 28 Jul 2022 | ₹1.99 Cr | Open |
Yes Bank Limited Creation Date: 06 Feb 2019 | ₹4.90 M | Open |
State Bank Of India Creation Date: 21 Jul 2003 | ₹288.98 Cr | Open |
How Many Employees Work at Symbiotec Pharmalab?
Symbiotec Pharmalab has a workforce of 1282 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Symbiotec Pharmalab, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Symbiotec Pharmalab's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
